JP7051693B2 - ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） - Google Patents

ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） Download PDF

Info

Publication number
JP7051693B2
JP7051693B2 JP2018543362A JP2018543362A JP7051693B2 JP 7051693 B2 JP7051693 B2 JP 7051693B2 JP 2018543362 A JP2018543362 A JP 2018543362A JP 2018543362 A JP2018543362 A JP 2018543362A JP 7051693 B2 JP7051693 B2 JP 7051693B2
Authority
JP
Japan
Prior art keywords
byl719
syndrome
pik3ca
pros
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018543362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505549A (ja
JP2019505549A5 (https=
Inventor
カノー，ギヨーム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Universite Paris Cite
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Universite de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Universite de Paris filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2019505549A publication Critical patent/JP2019505549A/ja
Publication of JP2019505549A5 publication Critical patent/JP2019505549A5/ja
Priority to JP2022012963A priority Critical patent/JP7847994B2/ja
Application granted granted Critical
Publication of JP7051693B2 publication Critical patent/JP7051693B2/ja
Priority to JP2024107982A priority patent/JP2024125429A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Spectrometry And Color Measurement (AREA)
JP2018543362A 2016-02-19 2017-02-17 ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） Active JP7051693B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022012963A JP7847994B2 (ja) 2016-02-19 2022-01-31 ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ）
JP2024107982A JP2024125429A (ja) 2016-02-19 2024-07-04 ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ）

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305193.1 2016-02-19
EP16305193 2016-02-19
PCT/EP2017/053587 WO2017140828A1 (en) 2016-02-19 2017-02-17 Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022012963A Division JP7847994B2 (ja) 2016-02-19 2022-01-31 ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ）

Publications (3)

Publication Number Publication Date
JP2019505549A JP2019505549A (ja) 2019-02-28
JP2019505549A5 JP2019505549A5 (https=) 2020-02-27
JP7051693B2 true JP7051693B2 (ja) 2022-04-11

Family

ID=55409795

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543362A Active JP7051693B2 (ja) 2016-02-19 2017-02-17 ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ）
JP2022012963A Active JP7847994B2 (ja) 2016-02-19 2022-01-31 ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ）
JP2024107982A Pending JP2024125429A (ja) 2016-02-19 2024-07-04 ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ）

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022012963A Active JP7847994B2 (ja) 2016-02-19 2022-01-31 ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ）
JP2024107982A Pending JP2024125429A (ja) 2016-02-19 2024-07-04 ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ）

Country Status (8)

Country Link
US (4) US11433059B2 (https=)
EP (1) EP3416642A1 (https=)
JP (3) JP7051693B2 (https=)
KR (1) KR20180115297A (https=)
CN (3) CN118477076A (https=)
AU (3) AU2017219834B2 (https=)
CA (1) CA3013845C (https=)
WO (1) WO2017140828A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016265844B2 (en) 2015-05-15 2021-02-11 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
EP3416642A1 (en) 2016-02-19 2018-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)
KR20210124310A (ko) 2019-02-06 2021-10-14 벤테라, 인코포레이티드 국소 포스포이노시티드 3-키나제 억제제
JP2024516006A (ja) * 2021-05-03 2024-04-11 ノバルティス アーゲー アルペリシブ製剤
WO2025045915A1 (en) * 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy
WO2025045129A1 (zh) * 2023-08-30 2025-03-06 广州嘉越医药科技有限公司 化合物用于治疗pros谱系疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583357B (zh) * 2006-08-29 2013-03-20 新加坡国立癌症中心 Mtor拮抗剂和血管生成抑制剂用于制备治疗癌症的药物的用途
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
UA118846C2 (uk) * 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
AU2016265844B2 (en) * 2015-05-15 2021-02-11 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
EP3416642A1 (en) 2016-02-19 2018-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Am J Hum Genet，2015年，Vol.97, No.6，p.914-21
GeneReviews [Internet]，2013年，p.1-30，URL=https://www.ncbi.nlm.nih.gov/books/NBK153722/pdf/Bookshelf_NBK153722.pdf

Also Published As

Publication number Publication date
AU2017219834B2 (en) 2022-06-30
US11433059B2 (en) 2022-09-06
JP2022058800A (ja) 2022-04-12
JP7847994B2 (ja) 2026-04-20
EP3416642A1 (en) 2018-12-26
KR20180115297A (ko) 2018-10-22
CN118477076A (zh) 2024-08-13
JP2019505549A (ja) 2019-02-28
US20250339417A1 (en) 2025-11-06
CA3013845C (en) 2024-09-17
AU2022235569A1 (en) 2022-10-13
CN109562103A (zh) 2019-04-02
US12427141B2 (en) 2025-09-30
US20250295645A1 (en) 2025-09-25
AU2022235569B2 (en) 2024-10-10
JP2024125429A (ja) 2024-09-18
AU2017219834A1 (en) 2018-08-23
CN118477075A (zh) 2024-08-13
WO2017140828A1 (en) 2017-08-24
US20200215044A1 (en) 2020-07-09
CA3013845A1 (en) 2017-08-24
AU2024278598A1 (en) 2025-01-16
US20220323428A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
JP7847994B2 (ja) ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ）
Budde et al. Tuberous sclerosis complex–associated angiomyolipomas: focus on mTOR Inhibition
Zhang et al. Mechanical stress regulates autophagic flux to affect apoptosis after spinal cord injury
KR20200098536A (ko) Dux4 발현과 관련된 질병의 치료를 위한 화합물
Marulanda et al. Emerging antenatal therapies for congenital diaphragmatic hernia-induced pulmonary hypertension in preclinical models
Cabezas et al. Central diabetes insipidus and Cushing's syndrome due to ectopic ACTH production by disseminated small cell lung cancer: a case report
JP7536987B2 (ja) 脈管奇形用医薬組成物及び脈管奇形の治療方法
JP2000514064A (ja) 敗血症誘導性急性腎不全および腎血管収縮ならびにカテコールアミン誘導性腎および腸管膜血管収縮の治療
JP2020503320A (ja) 術中低血圧に関連する損傷を減らす方法
HK40121190A (zh) 脉管畸形用药物组合物及脉管畸形的治疗方法
WO2026021478A1 (zh) Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法
Górska Diffuse alveolar hemorrhage in a chronically hemodialyzed patient with progressive necrotic skin lesions as a manifestation of calciphylaxis
TW202606680A (zh) 角化症用醫藥組成物及其用途
WO2026021460A1 (zh) 治疗前列腺癌的方法
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
Singh Therapeutic Ultrasound-Induced Insulin Release
Chen et al. 1Department of Critical Care Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, No. 136, Jingzhou Street, Xiangcheng District, Xiangyang 441021, Hubei, China. 2Department of Emergency Medicine, Xiangyang Central Hospital
Li et al. CFTR potentiation as a therapeutic strategy for pulmonary edema: a proof-of-concept study in pigs
Brackhan Investigation of brain inflammation as a nuclear imaging biomarker of epileptogenesis and a treatment target for epilepsy prevention
HK1214758A1 (en) S1p receptor modulators for treating multiple sclerosis
HK1214758B (en) S1p receptor modulators for treating multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211005

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20211208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220131

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220131

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220215

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220330

R150 Certificate of patent or registration of utility model

Ref document number: 7051693

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S633 Written request for registration of reclamation of name

Free format text: JAPANESE INTERMEDIATE CODE: R313633

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250